文献速递神经技术与安全CTMR

静脉流出时间延长——当静脉流出遇上经济流出:一项成本分析

Prolonged venous transit - where venous outflow meets financial outflow: a cost analysis.
PubMed 文献 · Neuroradiology · 2025-09-22

本研究回顾性纳入美国三个中心109例实现成功再灌注的急性大血管闭塞缺血性卒中患者,基于2025年CMS全国平均费用估算比较静脉流出时间延长(PVT+)与PVT-患者的急性期费用。PVT+患者急性卒中总费用中位数显著高于PVT-患者(36601美元 vs 24814美元,p=0.03),作者认为PVT+可能作为治疗前生物标志物辅助预判院内资源与费用。

要点

  • PVT+患者急性卒中总费用中位数36601美元,较PVT-患者的24814美元高11787美元(p=0.03)。
  • PVT+患者治疗后住院护理费用显著高于PVT-患者(p=0.03)。
  • PVT+是治疗前灌注影像上静脉流出不良的标志,可能辅助预判急性卒中院内费用。

核心结论

  • PVT+与其他临床数据结合,可能作为有用且多用途的治疗前生物标志物,用于预判急性卒中相关的院内资源与费用。

研究设计与样本

  • 回顾性研究,纳入美国三个中心109例实现成功再灌注(取栓)的成人急性大血管闭塞缺血性卒中患者。
  • 费用估算来自美国联邦医疗保险与医疗补助服务中心(CMS)2025年数据的全国服务平均费用。
  • 主要结局为急性干预、影像及治疗后住院护理至出院的总体费用估算,比较PVT+与PVT-队列。

关键影像表现/征象

  • PVT+为治疗前灌注影像上静脉流出不良的标志。
  • PVT+患者急性卒中总费用中位数36601美元(IQR 24814–72944),PVT-患者中位数24814美元(IQR 16956–48388),PVT+较PVT-高11787美元(p=0.03)。
  • PVT+患者治疗后护理费用显著高于PVT-患者(p=0.03)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Healthcare costs in large vessel occlusion acute ischemic stroke (AIS-LVO) patients vary widely despite achieving successful reperfusion. Prolonged venous transit (PVT+) is a new marker of poor venous outflow on pretreatment perfusion imaging associated with various patient outcomes. We aim to explore the relationship between PVT + and acute care cost estimates for AIS-LVO.

METHODS: Adult AIS-LVO patients achieving successful reperfusion with thrombectomy at three centers in the United States were retrospectively reviewed. Cost estimates were derived from national averages for services in the Centers for Medicare and Medicaid Services data (2025). The primary outcome was total cost estimates for acute intervention, imaging, and post-treatment inpatient care until discharge. Estimates were compared between PVT + and PVT- cohorts.

RESULTS: In 109 included patients, the median age was 71 years (IQR 62-80). The cost estimates for total acute stroke care were significantly greater by $11787 in PVT + patients (median $36601 [IQR $24814-$72944] than PVT- patients (median $24814 [IQR $16956-$48388], p = 0.03). Cost of post-treatment care was significantly greater in PVT + patients than PVT- patients (p = 0.03).

CONCLUSION: PVT + demonstrates potential as a useful, versatile pretreatment biomarker, in conjunction with other clinical data, to anticipate in-hospital resources and costs associated with acute stroke care.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Koneru M, Mei J, Salim H, et al. Prolonged venous transit - where venous outflow meets financial outflow: a cost analysis. Neuroradiology. 2025. PMID: 40982063. doi:10.1007/s00234-025-03774-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。